An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa

NCT02207816 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3084

Enrollment

INDUSTRY

Sponsor class

Conditions

Malaria

Interventions

PROCEDURE: Blood sampling
BIOLOGICAL: Malaria Vaccine 257049 (MALARIA-055 PRI)
BIOLOGICAL: Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)
BIOLOGICAL: Cell-culture rabies vaccine (MALARIA-055 PRI)
BIOLOGICAL: TritanrixHepB/Hib (MALARIA-055 PRI)
BIOLOGICAL: Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)

Sponsor

GlaxoSmithKline